RT Journal Article
SR Electronic
T1 Anemia of chronic kidney disease: When normalcy becomes undesirable
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 353
OP 356
VO 75
IS 5
A1 Demirjian, Sevag G.
A1 Nurko, Saul
YR 2008
UL http://www.ccjm.org/content/75/5/353.abstract
AB In patients with chronic kidney disease and renal failure, hemoglobin levels have been rising in parallel with more intensive use of erythropoiesis-stimulating agents (ESAs). However, several recent studies indicate that raising hemoglobin to normal levels with ESAs can be too much of a good thing. Compared with partial correction, normalization of hemoglobin did not improve outcome, and it may have led to more frequent adverse events. The US Food and Drug Administration (FDA) now recommends a hemoglobin goal in the range of 10 to 12 g/dL.